Search clinical trials for: 90Yttrium-Ibritumomab Tiuxetan

Total 96 results

Grupo Español de Linfomas y Transplante Autólogo...

Completed

Transplantation With Ybritumomab Tiuxetan (Zevalin) Plus BEAM Regimen in Patients With Refractory Large B-cell Difusse Lymphom (Z-BEAM LDGGB)

Non-Hodgkin's Lymphoma

Spain
AHS Cancer Control Alberta

Withdrawn

Efficacy and Safety of Treatment With a Single Dose of 90Y-ibritumomab Tiuxetan in Patients With Low Tumor Burden Untreated or Indolent NHL

Lymphoma

Canada
Mayo Clinic
National Cancer Institute (NCI)

Completed

Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma

Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma | Recurrent Mantle Cell Lymphoma | Recurrent Marginal Zone Lymphoma | Splenic Marginal Zone Lymphoma | Waldenstrom Macroglobulinemia | Recurrent... and other conditions

United States
AIDS Malignancy Consortium
National Cancer Institute (NCI)

Withdrawn

Combination Chemotherapy Followed by Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin's Lymphoma

Anaplastic Large Cell Lymphoma | AIDS-related Lymphoma | Adult Non-Hodgkin's Lymphoma
University of Miami

Completed

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Previously Untreated Marginal Zone Lymphoma

Marginal Zone Lymphoma

United States
University of Alabama at Birmingham
National Cancer Institute (NCI); Biogen

Completed

Radioimmunotherapy in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
Duke University
Spectrum Pharmaceuticals, Inc

Terminated

Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma

Mantle-Cell Lymphoma

United States
GlaxoSmithKline

Withdrawn

A Comparative Study Of Iodine I 131 Tositumomab Therapeutic Regimen Versus Ibritumomab Tiuxetan Therapeutic Regimen

Lymphoma, Follicular | Lymphoma, Non-Hodgkin | Lymphoma, Small Cleaved-Cell, Follicular | Lymphoma, Large-Cell, Follicular

United States
Centre Antoine Lacassagne

Completed

Combination Chemotherapy, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Newly Diagnosed Large B-Cell Lymphoma

Lymphoma

France
Boehringer Ingelheim

Completed

Study to Evaluate Safety, Tolerability and Pharmacokinetics of Increasing Repeated Oral Doses of Ambroxol Lozenges in Healthy Male Volunteers

Healthy
University Hospital Tuebingen

Completed

Radioimmunotherapy With 90Y-ibritumomab Tiuxetan as Part of a Dose Reduced Conditioning Regimen for Allogeneic Hematopoietic Cell Transplantation for the Treatment of Non-Hodgkin Lymphoma

Non-Hodgkin Lymphoma

Germany
Dana-Farber Cancer Institute
Massachusetts General Hospital; Biogen

Completed

Chemotherapy Followed by Zevalin for Relapsed Mantle Cell Lymphoma

Mantle Cell Lymphoma

United States
National Cancer Institute (NCI)

Completed

Rituximab, Prednisone, Cyclophosphamide, Doxorubicin, Vincristine, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Previously Untreated Mantle Cell Lymphoma

Lymphoma

United States, Australia, South Africa, Peru, Puerto Rico
Thies Schroeder

Completed

The Safety Evaluation of Aminophylline and Ambrisentan When Administered Orally Alone and in Combination to Healthy Volunteers (GQ01)

High Altitude Pulmonary Hypertension

United States
University of Alabama at Birmingham
National Cancer Institute (NCI)

Terminated

Radiolabeled Monoclonal Antibody in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
M.D. Anderson Cancer Center
Biogen

Completed

Radioimmunotherapy With 90Y Zevalin for Orbital Lymphoma

Lymphoma | Non-Hodgkin's Lymphoma

United States
Boehringer Ingelheim

Completed

Ambroxol Lozenges 20mg in Relieving the Pain of Sore Throat in Adolescent Patients With Acute Viral Pharyngitis

Pharyngitis

South Africa
M.D. Anderson Cancer Center
Biogen

Terminated

Ibritumomab Tiuxetan for Treatment of Non-Follicular CD20+ Indolent Lymphomas

Lymphoma

United States
Institut fuer anwendungsorientierte Forschung und...

Completed

A Study of Zevalin and Simultaneous Application of BEAM High-dose Chemotherapy Followed by Autologous Stem Cell Transplantation in Refractory and Relapsed Aggressive Non-Hodgkin Lymphomas (escZ-BEAM)

Primary Non-Hodgkin-Lymphoma | Refractory Non-Hodgkin-Lymphoma | CD20+ Aggressive Non-Hodgkin's Lymphoma

Germany
National Cancer Institute (NCI)

Completed

Yttrium Y 90 Ibritumomab Tiuxetan and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorder

Recurrent Adult Burkitt Lymphoma | Recurrent Adult Diffuse Large Cell Lymphoma | Waldenström Macroglobulinemia | Post-transplant Lymphoproliferative Disorder | Stage III Adult Burkitt Lymphoma | Stage III Adult Diffuse Large Cell Lymphoma | Stage IV Adult Burkitt Lymphoma | Stage IV Adult Diffuse...

United States
Memorial Sloan Kettering Cancer Center
National Cancer Institute (NCI)

Completed

Rituximab and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent Primary CNS Lymphoma

Lymphoma

United States
National Cancer Institute (NCI)

Terminated

Radiolabeled Monoclonal Antibody With or Without Peripheral Stem Cell Transplantation in Treating Children With Recurrent or Refractory Lymphoma

Post-transplant Lymphoproliferative Disorder | Recurrent Childhood Large Cell Lymphoma | Recurrent Childhood Lymphoblastic Lymphoma | Recurrent Childhood Small Noncleaved Cell Lymphoma | Recurrent/Refractory Childhood Hodgkin Lymphoma | AIDS-related Peripheral/Systemic Lymphoma | AIDS-related...

United States
National Cancer Institute (NCI)

Completed

Monoclonal Antibody Therapy and Peripheral Stem Cell Transplant in Treating Patients With Non-Hodgkin's Lymphoma

Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue | Recurrent Adult Diffuse Large Cell Lymphoma | Recurrent Adult Diffuse Small Cleaved Cell Lymphoma | Recurrent Grade 1 Follicular Lymphoma | Recurrent Grade 2 Follicular Lymphoma | Recurrent Grade 3 Follicular Lymphoma and other conditions

United States
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)

Terminated

Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Waldenstrom's Macroglobulinemia

Lymphoma

United States
Gruppo Italiano Multiregionale per lo studio dei...
Centro di Riferimento per l'Epidemiologia e la Prev. Oncologica Piemonte

Terminated

Zevalin Twice in Aggressive Non-Hodgkin Lymphoma

Diffuse Large B-Cell Lymphoma

Italy
Technical University of Munich

Unknown

Rituximab, Fludarabine, Cyclophosphamide, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed B-Cell Non-Hodgkin's Lymphoma

Lymphoma

Germany
Soroka University Medical Center

Unknown

Zevalin and BEAM High-dose Chemotherapy Compared With BEAM Alone as Conditioning Regimen in Patients With Chemosensitive Relapse of Non-Hodgkin's Lymphoma (Zevalin)

Non-Hodgkin's Lymphoma

Israel
Stanford University
National Institutes of Health (NIH); Biogen

Completed

90Y-IBRITUMOMAB Tiuxetan and AHCI With HD Chemotherapy and Autologous Transplantation for Relapsed or Resistant NHL

Lymphoma, Non-Hodgkin | Blood and Marrow Transplant (BMT)

United States
Northwestern University
National Cancer Institute (NCI)

Completed

Radiolabeled Monoclonal Antibody Therapy and High-Dose Chemotherapy Followed By Autologous Peripheral Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma

Lymphoma

United States
Oslo University Hospital

Completed

Zevalin-BEAM/BEAC With Autologous Stem Cell Support as Consolidation in First Line Treatment of Mantle Cell Lymphoma

Mantle Cell Lymphoma

Norway
CABYC
Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea

Completed

Safety Study to Evaluate Induction and Consolidation Treatment in Patients With Mantle Cell Lymphoma (LCM-04-02) (LCM-04-02)

Mantle Cell Lymphoma

Spain
Bayer

Completed

Zevalin Post-marketing Surveillance for Adequateness of Image Interpretation Criteria in Japan (ZEVALIN-SDUI)

Non-Hodgkin's Lymphoma (NHL)

Japan
M.D. Anderson Cancer Center
Biogen

Completed

Study Of Yttrium-ibritumomab (Zevalin) For the Treatment Of Patients With Relapsed And Refractory Mantle Cell Lymphoma

Lymphoma, Mantle-Cell

United States
SCRI Development Innovations, LLC
Biogen

Completed

Rituximab and Chemotherapy Followed by Ibritumomab Tiuxetan as Treatment for Low Grade Follicular Non-Hodgkin's Lymphoma

Non-Hodgkins Lymphoma
The Cleveland Clinic

Completed

External Beam Radiotherapy and Zevalin for Management of Indolent B-Cell Non-Hodgkin's Lymphoma

Lymphoma, B-Cell

United States
Chulalongkorn University
Bayer

Terminated

Yt90 Zevalin and Combination Chemotherapy (Z-CHOP)in Treating Patients With Stage II, Stage III, or Stage IV Diffuse Large B-cell Lymphoma

Diffuse Large B-cell Lymphoma

Thailand
Bayer

Completed

A Prospective Observational Study to Evaluate the Quality of Life and the Costs in a Real Life Setting in Patients Who Are Treated With 90Y-Zevalin

Lymphoma, Follicular | Non-Hodgkin Lymphoma

Belgium
Chonnam National University Hospital
Chonbuk National University Hospital; Samsung Medical Center; Pusan National... and other collaborators

Completed

90Y-ibritumomab Tiuxetan Consolidation After 6th R-CHOP Chemotherapy in Patients With Bulky Diffuse Large B Cell Lymphoma

Lymphoma, Large B-Cell, Diffuse

Korea, Republic of
University of Bologna

Completed

Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) Study in Patients With Follicular Grade I-II Lymphoma After 4 Cycles of Fludarabine-Mitoxantrone-Rituximab (FMR) Therapy (FM+R-Z)

Follicular Lymphoma

Italy
University of Bologna

Completed

Study to Evaluate the Efficacy and Safety of Subsequent Treatment With the Zevalin (Ibritumomab Tiuxetan) in Elderly (More Than 60 Years) Patients With Diffuse Large B Cell Lymphoma After 4 Cycles of CHOP21-Rituximab (CHOP21-R) Therapy (CHOP21+R-Z)

Diffuse Large B-Cell Lymphoma

Italy
Maisonneuve-Rosemont Hospital
Bayer

Unknown

Zevalin With Non Myeloablative Allogeneic Stem Cell Transplantation in Patients With Non Hodgkin Lymphoma

Non-Hodgkins Lymphoma

Canada
Bayer

Completed

Treatment With [90]Y-Ibritumomab Tiuxetan Versus no Treatment in Patients With Follicular Non Hodgkin Lymphoma (Stage III or IV) Having Achieved a Partial or Complete Remission After First Line Chemotherapy

Lymphoma, Non-Hodgkin

Belgium, France, Spain, Italy, Canada, Switzerland, Netherlands, United Kingdom, Portugal, Germany, Sweden, Denmark, Norway
Grupo Oncológico para el Tratamiento y el Estudio...

Unknown

Consolidation Treatment With Y90-Ibritumomab Tiuxetan After R-CHOP Induction in High Risk Patients According to Follicular Lymphoma International Prognostic Index (FLIPI) With Follicular Lymphoma (GOTEL-FL1LC)

Follicular Lymphoma

Spain
McGill University
McGill University Health Centre/Research Institute of the McGill University...

Unknown

Study Combining Zevalin With High-Dose Chemotherapy Prior to Autologous StemCell Transplant in Patients With Relapsed, Refractory, or Transformed Non-Hodgkin's Lymphoma (Zevalin)

Non-Hodgkin's Lymphoma

Canada
Biogen

Terminated

Safety and Efficacy of Zevalin in the Treatment of Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

United States
Lymphoma Study Association

Completed

Yttrium-90 Ibritumomab Tiuxetan (Zevalin) With BEAM in Relapsed Low Grade B-Cell Lymphoma

B-Cell Lymphoma

France, Belgium, Switzerland

3

Subscribe